{
    "id": 582,
    "fullName": "RET wild-type",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "Wild-type RET indicates that no mutation has been detected within the RET gene.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 5979,
        "geneSymbol": "RET",
        "terms": [
            "RET",
            "CDHF12",
            "CDHR16",
            "HSCR1",
            "MEN2A",
            "MEN2B",
            "MTC1",
            "PTC",
            "RET-ELE1"
        ]
    },
    "variant": "wild-type",
    "createDate": "05/15/2014",
    "updateDate": "08/01/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 2989,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iclusig (ponatinib) inhibited growth of small cell lung carcinoma lines expressing wild-type RET (PMID: 25122427).",
            "molecularProfile": {
                "id": 686,
                "profileName": "RET wild-type"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3555,
                    "pubMedId": 25122427,
                    "title": "RET mutation and expression in small-cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25122427"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2986,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Caprelsa (vandetanib) inhibited growth of small cell lung carcinoma lines expressing wild-type RET (PMID: 25122427).",
            "molecularProfile": {
                "id": 686,
                "profileName": "RET wild-type"
            },
            "therapy": {
                "id": 953,
                "therapyName": "Vandetanib",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3555,
                    "pubMedId": 25122427,
                    "title": "RET mutation and expression in small-cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25122427"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 686,
            "profileName": "RET wild-type",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}